← Eichor
Condition: Transitional Cell Cancer Of The Renal Pelvis And Ureter Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Transitional Cell Cancer Of The Renal Pelvis And Ureter

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Uppe
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05775471Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Phase 3 · 62 location(s) · UroGen Pharma Ltd. · NCT06774131Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
Phase 2/Phase 3 · 4 location(s) · University of British Columbia · NCT06124976Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary
Phase 2/Phase 3 · 258 location(s) · National Cancer Institute (NCI) · NCT04628767SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
Phase 2 · 1 location(s) · Rutgers, The State University of New Jersey · NCT06822010Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma
NA · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07630155uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Phase N/A · 22 location(s) · UroGen Pharma Ltd. · NCT05874921DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Phase 2 · 1 location(s) · Fudan University · NCT06354231Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
Phase 2 · 1 location(s) · RenJi Hospital · NCT05912816A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and U
NA · 1 location(s) · University of Washington · NCT06040762Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Phase 2 · 1 location(s) · Nagoya University · NCT06983210Translational Cancer Observational Protocol
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06169436A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treat
Phase 2 · 1 location(s) · Peking University First Hospital · NCT06210490The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract
Phase N/A · 5 location(s) · Zealand University Hospital · NCT070774479MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06823427Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and
Phase 4 · 1 location(s) · Mayo Clinic · NCT06764095Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/
Phase N/A · 1 location(s) · University of Washington · NCT01050504
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.